ArticleJournal of the National Cancer Institute2014

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Jung-Min Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.